Hematology Education Presentations

Expanding Hematology Knowledge

Innovative Hematology (IHI) is committed to partnering with providers across the state to ensure optimal outcomes for many rare disorders. IHI is home to the Indiana Hemophilia & Thrombosis Center (IHTC), the nation’s largest and Indiana’s only federally-designated hemophilia treatment center (HTC).

Innovative Hematology’s 20 adult and pediatric hematologists routinely share their expertise via Grand Rounds presentations, partnering with healthcare organizations to expand their staff’s knowledge to recognize benign hematologic presentations, understand treatment strategies and consider the impact of research on this area of medicine.

Continuing Education coordinators are encouraged to review the below menu of Hematology Grand Rounds presentation opportunities.

Anemia

• A General Approach to Anemia in Pediatrics
• Iron Deficiency in Children

Bleeding Disorders

• Bleeding Disorders in Pediatrics: From Birth & Beyond
  Learn how to approach a patient with a possible bleeding disorder through the exploration of hemophilia presentation and treatment as well as von Willebrand disease (VWD) presentation and treatment. Characterize rare bleeding disorders.
• Ecchymosis, Epistaxis & Bleeding – Oh My!
  Discuss a general approach for evaluation of pediatric patients with bleeding symptoms. Review the interpretation of screen laboratory tests to guide further evaluation. Delineate urgent evaluation and management of the bleeding pediatric patient.
• Emergency Management of the Pediatric Bleeding Patient
• Emergency Management of the Adult Bleeding Patient
  Review of massive hemorrhage in the previously healthy patient. Discuss patients with a diagnosed bleeding disorder as well as bleeding on anticoagulants.
• Hemophilia and Other Bleeding Disorders Overview
  Discuss the pathophysiology of hemophilias, von Willebrand Disease (VWD), and rare bleeding disorders. Delineate urgent evaluation and management of the bleeding adult or pediatric patient and female carriers.
• Hemophilia: Treatment, New Therapeutics & Optimal Outcomes
  Review the pathophysiology of hemophilia. Discuss current approaches to treatment including newly licensed treatment products. Describe the comprehensive approach to disease management. Explore strategies to improve outcomes (i.e., gene therapy, standardization of care, etc.).
• Interpretation of Coagulation Labs
• von Willebrand Disease Management and Other Bleeding Disorders OR Acquired Hemophilias
• Women’s/Menstrual Health
  An astounding 1 in 5 women with heavy menstural bleeding may have a bleeding disorder. This presentation discusses menstruation, pregnancy, and beyond in exploring the management of women with bleeding disorders. Content also covers the importance of utilizing bleeding scores to quantify blood loss/risk stratification, management.

HHT

• Hereditary Hemorrhagic Telangiectasia (HHT)

HVLM

• Strawberries & Blueberries: Every Vascular Anomaly is NOT a “Hemangioma”
• Hemangiomas, Vascular & Lymphatic Malformations in Children

Sickle Cell Disease

• Care Guidelines & Emergency Management of Patients with Sickle Cell Disease
• Sickle Cell Disease and Thalassemias: Past Successes and Future Direction
  Review the most common complications of SCD. Compares and contrasts the treatments for SCD and assesses how research studies will impact clinical care.

Thrombosis

• A Hematologist Approach to Pediatric Stroke
• Perinatal Stroke: Is it really harmless?
• Modern Management of Venous Thromboembolic Disease: An Evidence Based Approach
  Treatment of Venous Thromboembolic Embolism (VTE) has changed significantly with the advent of new medications in the post-coumadin era. It is vital for all practitioners to become familiar with these new agents and comfortable with their use and complications. Emerging data can guide therapy and change practice allowing for more effective treatment with fewer side effects and in particular medical emergencies.

Immunohematologic Disorders

• ITP: Immune Thrombocytopenic Purpura
  Having a prevalence of up to 12 per 100,000 in adults, ITP is a disease many hematologists are familiar. However, recent advances in therapy offer more options for both refractory and non-refractory ITP than ever before.
• TTP: Thrombotic Thrombocytopenic Purpura
  The treatment landscape for TTP has significantly advanced in the last few years with both the identification of new diagnoses for thrombotic microangiopathies and in the choice of therapeutic options for TTP.
  
• AIHA: Autoimmune Hemolytic Anemia
  Review the diagnostic challenges and treatment including newer developments in management in warm and cold autoimmune hemolytic anemia.
  
• HIT: Heparin-Induced Thrombocytopenia
  An acquired disorder of thrombosis associated with exposure to heparin leading to both arterial and venous blood clotting. Review pathophysiology, diagnosis and management of this common disorder.